Bausch & Lomb Incorporated

🇺🇸United States
Ownership
-
Established
1992-10-08
Employees
-
Market Cap
-
Website
Clinical Trials
Related News

A Study to Evaluate the Performance and Safety of Artelac Rebalance® Versus Vismed in the Management of Dry Eye

Not Applicable
Withdrawn
Conditions
Dry Eye
Interventions
Device: Artelac Rebalance
Device: Vismed
First Posted Date
2013-02-15
Last Posted Date
2013-10-11
Lead Sponsor
Bausch & Lomb Incorporated
Registration Number
NCT01791426

Bepotastine Besilate Nasal Sprays in the Treatment of Seasonal Allergic Rhinitis (SAR)

First Posted Date
2012-12-20
Last Posted Date
2020-10-05
Lead Sponsor
Bausch & Lomb Incorporated
Target Recruit Count
617
Registration Number
NCT01753739
Locations
🇺🇸

Bausch & Lomb Incorporated, Irvine, California, United States

Comparing the Safety and Efficacy of BOL-303259-X Ophthalmic Solution With Timolol Maleate Ophthalmic Solution in Subjects With Open-Angle Glaucoma or Ocular Hypertension

First Posted Date
2012-12-17
Last Posted Date
2018-11-21
Lead Sponsor
Bausch & Lomb Incorporated
Target Recruit Count
420
Registration Number
NCT01749930
Locations
🇺🇸

Bausch & Lomb Inc., Rochester, New York, United States

Comparing Safety and Efficacy of BOL-303259-X With Timolol Maleate in Subjects With Open-Angle Glaucoma or Ocular Hypertension

First Posted Date
2012-12-17
Last Posted Date
2018-11-07
Lead Sponsor
Bausch & Lomb Incorporated
Target Recruit Count
420
Registration Number
NCT01749904
Locations
🇺🇸

Bausch & Lomb Inc., Rochester, New York, United States

Clinical and Microbial Efficacy of Besifloxacin Ophthalmic Suspension, 0.6% in the Treatment of Bacterial Conjunctivitis

Phase 3
Terminated
Conditions
Bacterial Conjunctivitis
Interventions
Drug: Vehicle
Drug: Besifloxacin
First Posted Date
2012-12-04
Last Posted Date
2014-10-01
Lead Sponsor
Bausch & Lomb Incorporated
Target Recruit Count
136
Registration Number
NCT01740388
Locations
🇺🇸

Bausch & Lomb Incorporated, Rochester, New York, United States

Corneal Endothelial Cell Density Changes, When Mapracorat Ophthalmic Suspension 3%, is Administered for 14 Days

Phase 1
Completed
Conditions
Corneal Endothelial Cell Changes
Interventions
Drug: Mapracorat
First Posted Date
2012-11-29
Last Posted Date
2013-11-26
Lead Sponsor
Bausch & Lomb Incorporated
Target Recruit Count
61
Registration Number
NCT01736462
Locations
🇺🇸

Bausch & Lomb Inc, Rochester, New York, United States

Tear Fluid Levels of Loteprednol Etabonate Ophthalmic Gel 0.5% Following a Single Instillation

Phase 1
Completed
Conditions
Pharmacokinetics
Interventions
Drug: LE Gel
First Posted Date
2012-11-29
Last Posted Date
2013-11-08
Lead Sponsor
Bausch & Lomb Incorporated
Target Recruit Count
12
Registration Number
NCT01736527
Locations
🇺🇸

Bausch & Lomb Research Clinic, Rochester, New York, United States

Therapeutic Equivalence Study of Generic Brinzolamide vs Azopt

First Posted Date
2012-11-07
Last Posted Date
2023-05-09
Lead Sponsor
Bausch & Lomb Incorporated
Target Recruit Count
258
Registration Number
NCT01722604
Locations
🇺🇸

US01, Louisville, Kentucky, United States

BOL-303259-X With Timolol 0.5% in Subjects With Open-Angle Glaucoma or Ocular Hypertension

First Posted Date
2012-10-16
Last Posted Date
2018-09-04
Lead Sponsor
Bausch & Lomb Incorporated
Target Recruit Count
25
Registration Number
NCT01707381
Locations
🇺🇸

University of California San Diego, La Jolla, California, United States

Evaluation of Ocular Comfort With ISTA Tears vs Systane

Not Applicable
Completed
Conditions
Dry Eye Disease
Interventions
Drug: ISTA Tears
Drug: Systane
First Posted Date
2012-07-26
Last Posted Date
2024-10-08
Lead Sponsor
Bausch & Lomb Incorporated
Target Recruit Count
35
Registration Number
NCT01650584
Locations
🇺🇸

ISTA Pharmaceuticals, Inc., Irvine, California, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy